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Objectives: Little information exists on the acute treatment provided for rhi-
nosinusitis and its associated costs. We hypothesize that introducing the admin-
istration of mometasone furoate (MFNS) as a treatment for rhinosinusitis will 
have a substantial impact on medical resource costs, outcomes and possibly 
cost-effectiveness. The goal of this paper is to estimate the cost-effectiveness of 
treating patients with rhinosinusitis with MFNS versus amoxicillin. MethOds: A 
decision-analytic model was developed to estimate lifetime costs and outcomes 
associated with MFNS 200µg twice daily and amoxicillin 500mg three times daily 
in treating rhinosinusitis from the Mexican health care perspective. This study 
further do not included MFNS 200µg once daily as a treatment arm because it 
was not found to be superior to amoxicillin. Data sources included published 
literature, clinical trials, official price/tariff lists, and Delphi panel data. The time 
horizon was 2 weeks. The effectiveness outcomes of the study were modeled 
as changes in the Major Symptom Score (MSS). MSS consists of five questions 
concerning rhinorrhoea, post-nasal drip, nasal congestion, sinus headache, and 
facial pain. Costs were valued in US dollar, year 2012 values. Multiple 1-way 
sensitivity analyses and a probabilistic sensitivity analysis using Monte Carlo 
simulation were performed to handle uncertainty. Results: The projected costs 
were US$ 258 with MFNS and $US 272 with. The benefits (changes in the MSS) were 
0.52 with MFNS 0.45 with Amoxicilin. MFNS was associated with a cost savings 
per patient of US$ 14 versus amoxicillin over a period of 2 weeks from a health 
care perspective. The incremental cost-effectiveness ratio for MFNS dominated 
Amoxicilin. Sensitivity analysis confirmed the overall cost savings and gains 
in effectiveness. cOnclusiOns: Our analysis suggests MFNS improves health 
outcomes in a cost-effective manner compared with Amoxicilin. The economic 
value of Amoxicillin is influenced by difficulties involved in diagnosing the condi-
tion, effectiveness, resistance, patient compliance with treatment, and treatment 
failure associated with antibiotics.
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Objectives: Pharmaceutical spending in Mexico represents approximately 25% of 
total health expenditures, with this number expected to grow by 14% from 2009-
2014. 90% of Mexico’s population receives health care from the public health system 
or Popular Health Insurance (PHI). A private insurance market has begun to take root. 
This study looks at how the increase in price controls and guidelines may impact 
access to newly approved Community Acquired Pneumonia (CAP) drugs. MethOds: 
An array of published data such as pricing process, current policies, sector-specific 
research articles contributed towards a framework to understand the key factors 
affecting access to CAPs drugs, were gathered. The data then informed a telephone 
survey of national and regional health care stakeholders (N= 6). Results: Findings 
show that in Mexico: 1) New pressures through price negotiations are occurring 
due to economic challenges facing PHI; 2) Private purchasing of pharmaceutical 
products represents 56% of sold units worth 79% of total spend versus public pur-
chase representing 44% of sold units and 21% of total spend; 3) Formularies used by 
public coverage schemes require newly approved drugs for CAP to achieve marketing 
authorization, meet safety requirements and be cost effective versus comparator 
agents; and 4) International reference price serves as a benchmark for establish-
ing a price threshold. cOnclusiOns: Drugs used to treat CAP are compared to 
comparator agents based on cost effectiveness. This will determine placement in 
the public formulary. The private pharmaceutical market may use data from the 
public formulary system when making a determination on price. Existing clinical 
guidelines in the public sector are non-binding, leaving the final decision on use 
to physicians. However, patient access to drugs for CAP may be impacted based on 
price negotiations and cost effectiveness analysis.
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Objectives: To assess the knowledge, perception and practices with respect 
to antibiotic usage amongst the Indian population with an aim to sensitize the 
survey participants about the consequences of misuse of antibiotics. MethOds: 
A questionnaire was designed around the use, misuse and consequences of anti-
biotic resistance based on latest National Policy for Antimicrobial Resistance of 
India. The survey was conducted using social media sites like facebook, twitter 
etc. The responses collected were classified as geographical locations, gender, 
age and occupation. Survey is designed in such a way that all the prevailing 
practices and views of the general public with respect to antibiotic usage are 
covered. Results: The prescription for antibiotic was 25% for common cold. 
Empirical antibiotic prescription was reported for 61% of the respondents. 14% 
preferred for a diagnostic test for guiding antibiotic prescription by doctors. 50% 
of the respondents preferred to purchase antibiotics directly from the chemist 
shops without the prescription of a doctor. Almost half of the respondents were 
not aware about the antibiotic resistance development due to environmental con-
tamination. 35% of the respondents affirmed to stopping the antibiotic regimen 
as soon as their symptoms subsided. cOnclusiOns: The antibiotic resistance 
is a global phenomenon requiring the immediate reforms to curb as the danger 
of multi-drug resistant bacteria is a ticking time bomb. Our results have clearly 
indicated the misuse of antibiotics by public and practitioners which needs to 
be monitored and corrected immediately to prevent the catastrophe of epidem-
ics by MDR bacteria as the new antibiotics are not invented and old drugs are 
becoming ineffective.
responsible for an enormous burden of disease in the region. This evidence-based, 
internally and externally valid HEM showed to be an adequate tool for the assess-
ment of the effects of smoking and could be a useful policy-making tool to estimate 
the cost-effectiveness of tobacco control interventions.
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ObjetivOs: Comparar os custos do tratamento de crianças hospitalizadas por pneu-
monia bacteriana adquirida na comunidade, considerando diferentes metodolo-
gias de custeio. MétOdOs: Estudo prospectivo realizado em Goiânia, Goiás/Brasil. 
Crianças com 28 dias a 35 meses internadas em 2 hospitais foram avaliadas. Três 
metodologias de custeio foram consideradas na perspectiva do Sistema Único de 
Saúde: (i) bottom-up/micro-costing através da revisão de prontuários; (ii) top-down/
micro-costing através de diretriz terapêutica; e (iii) top-down/gross-costing através 
de ressarcimento pago pelo SUS. Casos foram pacientes internados com suspeita 
clínica de pneumonia, receberam antibioticoterapia durante a internação e não 
tiveram diagnóstico final de pneumonia viral. Casos graves foram aqueles interna-
dos em enfermaria enquanto os internados em unidade de terapia intensiva foram 
considerados muito graves. Foram considerados custos diretos (medicamentos, 
honorários médicos e de fisioterapia respiratória, exames e diárias hospitalares 
em UTI e enfermaria) e não-médicos (diárias de acompanhantes). Os custos foram 
estimados em dólares americanos (USD) e reais (R$) considerando a taxa de câmbio 
oficial (1 USD = R$ 1,875) em dezembro de 2011. O teste de Friedman foi utilizado 
para comparar os resultados. ResultAdOs: Foram analisados 59 casos (52 graves 
e 7 muito graves). Os custos de casos graves foram R$ 781 (USD 416) por bottom-up/
micro-costing, R$ 641 (USD 342) por top-down/micro-costing e R$ 597 (USD 318) por top-
down/gross-costing (p= 0,015). Para os casos muito graves, os custos foram R$ 3.539 
(USD 1.887) por bottom-up/micro-costing, R$ 3.369 (USD 1.796) por top-down/micro-
costing e R$ 3.175 (USD 1.693) por top-down/gross-costing (p= 0,018). Para ambos os 
grupos, houve diferença significativa apenas entre bottom-up/microcosting e top-down/
gross-costing. cOnclusões: Nossos resultados sugerem a estimativa de custos por 
top-down/micro-costing através de diretriz terapêutica pode ser uma alternativa que 
se aproxima à estimativa considerando o bottom-up/microcosting através de revisão 
de prontuários, considerado o padrão ouro para estimativa de custos de doença.
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Objectives: To assess the effectiveness and costs of the Smoking Cessation Program 
(SCP) in the Public Unified Health System (SUS) and to estimate the cost for its full 
implementation in the city of Goiânia, Brazil. MethOds: The SCP intervention targets 
group of smokers, and includes medical visits, cognitive-behavioral group therapy, 
and medication use, lasting six months. Costs for SCP intervention and manage-
ment were estimated. The SCP full implementation was defined as the program’s 
expansion to meet the demand of all smokers motivated to quit smoking in the city 
of Goiânia. Direct medical and non-medical direct costs were considered, including 
staff, medications, consumables, general expenses, transportation, travel, events and 
capital costs. Microcosting and activity-based costing methods were used. Cost for 
the federal, state and municipal levels were estimated. The SUS perspective was 
considered. Two-way sensitivity analysis was conducted. Data sources included a 
convenience sample of primary health facilities, municipal and state health depart-
ments, and the Ministry of Health. Costs were estimated in Reais (R$) and U.S. Dollars 
(USD), considering the exchange rate of December/2010, which was 1.67. Quitting rates 
were estimated as the percentage of patients who reported not smoking at the end 
of the intervention. Costs of the SCP are presented as total cost of the intervention; 
costs stratified by component and level of funding source; cost per patient; and cost 
per quitter. Results: The average quitting rate was 37.2%. The cost of SCP in Goiânia 
was R$428,580 (US$257,220), of which 23% were program management costs. Cost 
per patient was R$534 (US$320) and cost per quitter was R$1,433 (US$860). The SCP’s 
full implementation reaching the estimated 37,455 smokers in Goiânia motivated to 
quit would cost R$21.5 million (US$13). cOnclusiOns: The SCP is highly effective. 
Additional efficiency could be gained by expanding patient’s access to the program.
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